SHANGHAI, Feburary 3rd, 2026 —— The landscape of hepatitis B (HBV) treatment is undergoing a historic transformation, shifting from long-term viral suppression to the pursuit of functional cure. As commercialization milestones draw near in 2026, the race to reshape the HBV drug market is heating up.
CIC's Director Kyle Lu shared key insights in a recent interview with Cailian Press:
Current Market Dynamics: Nucleos(t)ide analogues (NAs) remain the mainstay of HBV treatment, focusing on viral suppression with fierce competition including generics. Interferons are gaining traction but face constraints from adverse reactions and patient compliance.
Game-changing Innovations: Breakthrough therapies are poised to redefine the market. GSK/Ionis’ bepirovirsen (an ASO) has delivered positive Phase III results and is on track for global regulatory submissions in Q1 2026. Haobio’s AHB-137 also stands out with impressive clinical data, boasting best-in-class potential for functional cure.
R&D Focus Areas: The future of HBV drug development lies in multi-mechanism combination strategies. This includes RNA therapies (ASO, siRNA) to reduce HBsAg and viral protein load, capsid inhibitors to disrupt viral replication and cccDNA replenishment, and immunomodulatory approaches (TLR agonists, therapeutic vaccines, PD-1/PD-L1 inhibitors) to restore exhausted T and NK cells for sustained immune control.
Synergy is Key: Combination of innovative therapies with antiviral agents will be a core development direction, exploring patient populations eligible for sustained HBsAg clearance after treatment discontinuation. NAs will remain the foundation of treatment in the near term, with their patient share expected to stay stable or even grow.
As the industry marches toward the functional cure era, how will these innovations reshape market competition and patient access?
Some viewpoints in this article are featured in the report of Cailian Press: The Race for HBV Clinical Cure Intensifies: 2026 May Mark a Critical Juncture for Commercialization
Cailian Press Reporter: Shi Shiyun; Editor-in-Charge: Xu Hong
About CIC
CIC is a professional consulting firm offering tailored end-to-end support across the full investment and financing lifecycle. The firm boasts a world-leading track record in guiding landmark first-in-sector IPOs across global markets, alongside unrivaled reach and in-depth coverage capabilities across specialized niche market segments.
CIC helps enterprises refine scalable business models and craft compelling capital narratives to enable seamless access to global capital markets, while serving as a trusted due diligence partner to investment institutions. It delivers granular industry insights and direct access to subject matter experts, empowering clients to identify high-value opportunities and mitigate critical risks effectively.
Media Contact
marketing@cninsights.com